LRB-4215/1
JAM:cjs&emw
2023 - 2024 LEGISLATURE
2023 ASSEMBLY BILL 753
December 6, 2023 - Introduced by Representatives GUSTAFSON, C. ANDERSON,
BROOKS, EDMING, MURPHY, SAPIK, J. ANDERSON, BARE, CONSIDINE, EMERSON,
JACOBSON, JOERS, OHNSTAD, ORTIZ-VELEZ, RATCLIFF, SHANKLAND, SINICKI and
HAYWOOD, cosponsored by Senators JAMES, HESSELBEIN, AGARD, LARSON, ROYS
and SPREITZER. Referred to Committee on Health, Aging and Long-Term Care.
***AUTHORS SUBJECT TO CHANGE***
AN ACT to create 20.285 (1) (qh), 20.285 (1) (qi), 25.14 (1) (a) 14m., 25.17 (1) (jw),
25.51 and 36.25 (16) of the statutes; relating to: creating a medicinal
psilocybin treatment fund and a pilot program to study the effects of medicinal
psilocybin treatment on patients with post-traumatic stress syndrome at the
University of Wisconsin-Madison and making an appropriation.
Analysis by the Legislative Reference Bureau
This bill creates a new separate nonlapsible trust fund designated as the
medicinal psilocybin treatment fund and establishes a pilot program to study the
effects of medicinal psilocybin treatment on patients with post-traumatic stress
syndrome (PTSD).
The medicinal psilocybin treatment pilot program created by this bill must be
established by the Board of Regents of the University of Wisconsin System at the
University of Wisconsin-Madison in collaboration with that institution's
Transdisciplinary Center for Research in Psychoactive Substances and its School of
Pharmacy. The individuals eligible to participate in the pilot program must be
veterans who are 21 years of age or older and who suffer from treatment-resistant
PTSD. Individuals who are law enforcement officers are not eligible to participate
in the pilot program study. The psilocybin therapy provided by the pilot program
must be provided through pathways approved by the federal Food and Drug
Administration, and the research accomplished in the pilot program may be
accomplished in conjunction with other medications approved by the federal Food
1
2
3
4
5 - 2 -2023 - 2024 Legislature LRB-4215/1
JAM:cjs&emw
ASSEMBLY BILL 753
and Drug Administration. The board must ensure that no health information
disclosed in the course of conducting the program contains personally identifiable
information. The researchers conducting the program must create reports for the
governor and the appropriate standing committees of the legislature regarding
progress of the pilot program and the studies conducted as part of the program.
The medicinal psilocybin treatment fund created in this bill consists of
donations, gifts, grants, bequests, moneys transferred from the general fund, and all
earnings and other investment income of the fund. This trust fund is managed by
the State of Wisconsin Investment Board. Moneys in the fund may be expended for
the purpose for which any donation, gift, grant, or bequest is made and for the
administration of the pilot program.
For further information see the state fiscal estimate, which will be printed as
an appendix to this bill.
The people of the state of Wisconsin, represented in senate and assembly, do
enact as follows:
SECTION 1. 20.005 (3) (schedule) of the statutes: at the appropriate place, insert
the following amounts for the purposes indicated:
2023-24 2024-25
20.285 University of Wisconsin System
(1) UNIVERSITY EDUCATION, RESEARCH AND PUBLIC
SERVICE
(qh)Medicinal psilocybin treatment
pilot program SEG A 100,000 -0-
SECTION 2. 20.285 (1) (qh) of the statutes is created to read:
20.285 (1) (qh) Medicinal psilocybin treatment pilot program. From the
medicinal psilocybin treatment fund, the amounts in the schedule for the operations
of the medicinal psilocybin treatment pilot program under s. 36.25 (16).
SECTION 3. 20.285 (1) (qi) of the statutes is created to read:
1
2
3
4
5
6
7
8
9
10
11
12 - 3 -2023 - 2024 Legislature
LRB-4215/1
JAM:cjs&emw
SECTION 3
ASSEMBLY BILL 753
20.285 (1) (qi) Medicinal psilocybin treatment pilot program donations, gifts,
grants, and bequests. From the medicinal psilocybin treatment fund, all moneys
received from donations, gifts, grants, and bequests to the medicinal psilocybin
treatment pilot program under s. 36.25 (16) to carry out the purpose for which
received.
SECTION 4. 25.14 (1) (a) 14m. of the statutes is created to read:
25.14 (1) (a) 14m. The medicinal psilocybin treatment fund.
SECTION 5. 25.17 (1) (jw) of the statutes is created to read:
25.17 (1) (jw) The medicinal psilocybin treatment fund (s. 25.51).
SECTION 6. 25.51 of the statutes is created to read:
25.51 Medicinal psilocybin treatment fund. There is established a
separate nonlapsible trust fund designated as the medicinal psilocybin treatment
fund. The fund shall consist of all of the following:
(1) Donations, gifts, grants, and bequests deposited into the fund under s. 36.25
(16) (b).
(2) Moneys transferred under s. 36.25 (16) (c).
(3) All earnings and other investment income of the fund.
SECTION 7. 36.25 (16) of the statutes is created to read:
36.25 (16) MEDICINAL PSILOCYBIN TREATMENT PILOT PROGRAM. (a) 1. The board
shall establish at the University of Wisconsin-Madison in collaboration with that
institution's transdisciplinary center for research in psychoactive substances and its
school of pharmacy a pilot program to study the effects of medicinal psilocybin
treatment on patients with post-traumatic stress syndrome and related
comorbidities.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24 - 4 -2023 - 2024 Legislature LRB-4215/1
JAM:cjs&emw
SECTION 7 ASSEMBLY BILL 753
2. The individuals eligible for the pilot program under subd. 1. shall be
veterans, as defined by the board, who are 21 years of age or older and who suffer
from treatment-resistant post-traumatic stress syndrome. An individual who is a
law enforcement officer, as defined in s. 165.85 (2) (c), or a tribal law enforcement
officer, as defined in s. 165.85 (2) (g), may not participate in the pilot program under
subd. 1.
3. The pilot program under subd. 1. shall provide psilocybin therapy through
pathways approved by the federal food and drug administration.
4. The pilot program under subd. 1. may accomplish its research in conjunction
with other medications approved by the federal food and drug administration.
5. The board shall ensure that no health information disclosed by the pilot
program under subd. 1. contains personally identifiable information, as defined
under s. 19.62 (5).
6. On the first day of the 6th month beginning after the effective date of this
subdivision .... [LRB inserts date], and every 6 months thereafter while the pilot
program under subd. 1. continues, the board shall submit to the governor and to the
appropriate standing committees of the legislature under s. 13.172 (3) a report
prepared by the researchers conducting the pilot program that details the progress
of the pilot program's study.
7. Within 6 months of the completion of a study in the pilot program under subd.
1., the board shall submit to the governor and to the appropriate standing
committees of the legislature under s. 13.172 (3) a report prepared by the researchers
conducting the study detailing the results of the study and any recommendations for
legislation based on the study results.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24 - 5 -2023 - 2024 Legislature
LRB-4215/1
JAM:cjs&emw
SECTION 7
ASSEMBLY BILL 753
8. Within 6 months of the completion of the pilot program under subd. 1., the
board shall submit to the governor and to the appropriate standing committees of the
legislature under s. 13.172 (3) a report prepared by the researchers conducting the
pilot program detailing the final results of the pilot program and any
recommendations for legislation based on the pilot program's results.
(b) The board, the University of Wisconsin-Madison, the University of
Wisconsin-Madison's school of pharmacy and the program under par. (a) 1. may
receive donations, gifts, grants, and bequests to the program and use any donation,
gift, grant, or bequest for the purpose for which it is made. The board shall deposit
the amount of any donation, gift, grant, or bequest into the medicinal psilocybin
treatment fund.
(c) The secretary of administration shall annually transfer from the general
fund to the medicinal psilocybin treatment fund the amount in the schedule under
20.285 (1) (qh) for the applicable fiscal year.
(END)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15